Angiotensin receptor blockers therapy and cancer risk

Published: 1 August 2019
Author(s): Shih-Wei Lai
Issue: August 2019
Section: Letter to the Editor

Angiotensin receptor blockers are widely prescribed to treat hypertension. The relationship between angiotensin receptor blockers and cancer is extensively studied. Recently one meta-analysis conducted by Datzmann et al. published in Eur J Intern Med reported no relationship between angiotensin receptor blockers therapy and cancer risk [1]. I appreciate Datzmann et al’ efforts to indicate a new research direction on cancer therapy. Some points are discussed with the readers. First, one cohort study not included in Datzmann et al.'s analysis revealed that angiotensin receptor blockers use was associated with a lower risk of gastro-esophageal cancer death than the non-use (hazard ratio = 0.83, 95% confidence interval 0.71–0.98) [2].